Product Description
Mechanisms of Action: HO-1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mallinckrodt
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Kernicterus|Hyperbilirubinemia, Neonatal|Jaundice, Neonatal
Phase 2: Hyperbilirubinemia, Neonatal|Jaundice, Neonatal|Porphyrias|Porphyria, Erythropoietic|Obstetric Labor, Premature|Hemolytic Disease of the Fetus and Newborn|Glucosephosphate Dehydrogenase Deficiency
Phase 1: Porphyrias|Porphyria, Erythropoietic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JASMINE_205 | N/A |
Completed |
Hyperbilirubinemia, Neonatal |
2020-02-28 |
|
| ISNHP | N/A |
Terminated |
Other |
2016-05-10 |
|
| JASMINE_204 | P2 |
Completed |
Hyperbilirubinemia, Neonatal|Jaundice, Neonatal |
2016-03-22 |
|
| 2009-018267-27 | P2 |
Completed |
Hyperbilirubinemia, Neonatal |
2015-10-11 |